Show simple item record

dc.contributor.authorBerro, Mariano.
dc.contributor.authorRivas, María.
dc.contributor.authorTrucco, José.
dc.contributor.authorEt al.
dc.date.accessioned2023-10-09T15:45:15Z
dc.date.available2023-10-09T15:45:15Z
dc.date.issued2021-04
dc.identifier.citationBone Marrow Transplant . 2021 Apr;56(4):986-988.es
dc.identifier.issn1476-5365
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/2315
dc.descriptionDisponible en: https://www.nature.com/articles/s41409-020-01146-0es
dc.description.abstractPost-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experiencees
dc.language.isoenes
dc.publisherSpringer Naturees
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPost-transplant cyclophosphamidees
dc.subjectHematopoietic stem cell transplantationes
dc.subjectAntithymocyte globulines
dc.titlePost-transplant cyclophosphamide demonstrates lower non-relapse mortality and better graft-versus-host disease/relapse-free survival compared with antithymocyte globulin in unrelated donor hematopoietic stem cell transplantation. A single-center experiencees
dc.typeArticlees


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional